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Selective trihydroxylated azepane inhibitors of
NagZ, a glycosidase involved in Pseudomonas
aeruginosa resistance to β-lactam antibiotics†
J. Bouquet,a D. T. King,b G. Vadlamani,c G. R. Benzie,c B. Iorga, d D. Ide,e
I. Adachi,e A. Kato,*e D. J. Vocadlo,b B. L. Mark,*c Y. Blériot *a and J. Désiré*a
The synthesis of a series of D-gluco-like configured 4,5,6-trihydroxyazepanes bearing a triazole, a sulfo-
namide or a fluorinated acetamide moiety at C-3 is described. These synthetic derivatives have been
tested for their ability to selectively inhibit the muropeptide recycling glucosaminidase NagZ and to
thereby increase sensitivity of Pseudomonas aeruginosa to β-lactams, a pathway with substantial thera-
peutic potential. While introduction of triazole and sulfamide groups failed to lead to glucosaminidase
inhibitors, the NHCOCF3 analog proved to be a selective inhibitor of NagZ over other glucosaminidases
including human O-GlcNAcase and lysosomal hexosaminidases HexA and B.
Introduction
β-Lactam antibiotics are the mainstay treatment for bacterial
infections, constituting over 50% of all antibiotics in clinical
use. Their therapeutic efficacy however, is being steadily
eroded by the increasing prevalence of bacterial resistance
mechanisms.1 A formidable mechanism of β-lactam resistance
in Gram-negative bacteria is the production of the inducible
AmpC β-lactamase,2 an enzyme that deactivates most
β-lactams, including penicillins, cephems and monobactams.
AmpC is produced by Pseudomonas aeruginosa, a pathogen that
is the leading cause of chronic lung infections and mortality
among people with cystic fibrosis, and a major cause of severe
hospital-acquired infections. AmpC induction depends on the
activity of the highly conserved peptidoglycan (PG) recycling
pathway of Gram-negative bacteria.3 β-Lactams activate this
pathway, and during prolonged therapy, mutations that cause
constitutive AmpC hyperproduction inevitably arise in
P. aeruginosa. These mutations confer resistance to the
majority of β-lactams and is the foremost cause of the thera-
peutic failure of β-lactams against P. aeruginosa. Recently, the
AmpC inhibitor avibactam in combination with ceftazidime
has been clinically approved and works effectively against
P. aeruginosa.4 Most clinically available β-lactamase inhibitors,
however, are ineffective against AmpC-mediated resistance and
direct targeting of AmpC could lead to the rapid evolution of
resistance. Accordingly, new strategies to indirectly block
AmpC activity are a topic of considerable interest.5
One other potential strategy to fight inducible AmpC would
be to inhibit one step in the peptidoglycan pathway by target-
ing the cytosolic glycoside hydrolase (GH) NagZ with small
molecule inhibitors. NagZ is a member of CAZy family GH36
that catalyzes the hydrolysis of cytosolic GlcNAc (1–4)-1,6-
anhydroMurNAc-peptide to yield free GlcNAc and anhMurNAc-
peptide (Fig. 1b), which is the ligand that induces transcrip-
Fig. 1 (a) Structure of NagZ inhibitors 1–6; (b) action of NagZ on pepti-
doglycan cell wall fragments.
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modification, we also examined fluorinated acyl moieties that
had previously proved beneficial in the case of an iminosugar
targeting heparanase, another GlcNAc processing glyco-
sidase.25 To validate such structural modifications, docking
experiments were first conducted using the crystal structure of
the 1.8 Å resolution complex of Burkholderia cenocepacia NagZ
(BcNagZ) (PDB 4MSS) from which the AzeNAc inhibitor 5 has
been removed. The in silico experiments were performed using
GOLD software26 (Fig. 2).
Except for the hydroxyl group beta to the nitrogen, a fairly
good superimposition between the docked analogues bearing
a methyltriazole, methylsulfonamide or fluorinated acetamide
and the parent iminosugar is observed, which encouraged us
to pursue their synthesis.
Synthesis
The known azidoazepane 7 27 available in 11 steps from
β-D-glucose pentaacetate was used as common precursor for all
the syntheses described in this work.
Synthesis of triazole derivatives. The Cu(I) catalysed 1,3-
dipolar cycloaddition of azides and terminal alkynes is the
most popular strategy to access 1,2,3-triazoles. However, low
molecular weight alkynes, typically C2 to C5 derivatives that
are of interest to us, are generally under-represented as sub-
strates in CuAAC reactions due to their volatility. Preliminary
Fig. 2 A: Docking conformation of BcNagZ/azepane 5 (green sticks).
B: Superimposition of crystal structure (light blue sticks) and docked struc-
ture of BcNagZ/azepane 5. C: Superimposition of crystal structure of
BcNagZ/azepane 5 and methyltriazolo azepane 9a. D: Superimposition
of crystal structure of BcNagZ/azepane 5 and methylsulfonamido
azepane 11a. E: Superimposition of crystal structure of BcNagZ/azepane
5 and trifluoroacetamido azepane 13a. Non carbon atoms are colored
by type (O: red; N: dark blue; F: green; S: yellow). The blue structure rep-
resents the 1.8 Å resolution crystal structure of 5 bound to BcNagZ (PDB
ID: 4MSS).
tion of AmpC. These two recycling fragments are ultimately 
recycled as precursors in central metabolism and PG bio-
synthesis. NagZ uses a two-step, double displacement mecha-
nism involving the formation and breakdown of a covalent 
glycosyl–enzyme intermediate.7–9 Significantly, the 2-acet-
amido group of the GlcNAc residue of the substrate is not 
involved in catalysis. Guided by these detailed structural and 
mechanistic studies of NagZ, several inhibitors including com-
pounds 1–6 10–14 (Fig. 1a) have been pursued as a strategy to 
block AmpC production and shown to potentiate the efficacy 
of co-administered β-lactams against P. aeruginosa.15 
Co-administration of the inhibitors with frontline β-lactam 
ceftazidime significantly reduces the minimal inhibitory con-
centration (MIC) of these β-lactams against AmpC hyper-
producing mutants of P. aeruginosa, thereby demonstrating 
that our approach can revitalize the usefulness of these anti-
biotics against the pathogen. Interestingly, it has also been 
shown that genetic inactivation of NagZ suppress the emer-
gence of highly resistant AmpC hyper producing mutants,16 
suggesting that NagZ inhibitors may also suppress the develop-
ment of β-lactam resistance.
While being a submicromolar inhibitor of NagZ, imino-
sugar 5 (AzeNAc) proved to be also a potent inhibitor of func-
tionally related human glycosidase O-GlcNAcase (OGA)17 and 
lysosomal β-hexosaminidase HexA. Examination of the active 
sites of these enzymes that belong to the GH84 and GH20 
families respectively revealed that the pocket interacting with 
the 2-acetamido group differs.18 In this work, we have explored 
this structural discrepancy and incorporated N-acyl substi-
tuents of various sizes as well as acetamide bio-isosteric substi-
tuents with the aim of improving the selectivity and potency of 
this seven-membered ring scaffold towards NagZ enzymes.
Results and discussion
Several groups have shown that precise structural modi-
fications of N-acetyl-D-glucosamine-based iminosugars can 
bias their inhibition profile toward a specific N-acetyl-D-
glucosaminidase of therapeutic interest.19–22 In the case of 
NagZ, selectivity can be achieved through modification of the 
acetamide moiety. Increasing the alkyl chain length up to 3 or 
4 carbons provides potent and selective molecules. When 
applied to AzeNAc 5, such modification led to inhibitors such 
as 6 that were more selective toward NagZ over OGA but also 
less potent.14 The NagZ-azepane 6 crystal structure23 revealed 
the presence of an extensive pocket with space available to 
accommodate modified acetamide moieties. Therefore, we 
postulated that replacement of the acetamide group by bio-
isosteric functionalities could be tolerated by the enzyme and 
might generate more potent and selective inhibitors. We first 
focused on triazole and sulfonamide groups that have proven 
useful as replacements for acetamide groups in medicinal 
chemistry.24 Moreover, the enzymatic pocket is surrounded by 
three histidine residues that might accommodate functions 
with distinct electronic properties. Therefore, as a more subtle
The library of derivatives was next assayed on the human
relevant NagZ, OGA and a preparation of isolated lysosomal
β-hexosaminidases HexA and B (HexAB) enzymes.
Inhibition of NagZ, OGA and HexAB. To analyse the relative
ability of the azepanes to inhibit NagZ, OGA, and HexAB we
used a continuous assay using the chromogenic substrate
para-nitrophenyl 2-acetamido-2-deoxy-β-D-glucopyranoside
(pNP-GlcNAc). We first selected a representative compound of
each set of azepanes, namely the methyl analogs 9a, 11a and
13a. We found that replacing the N-acyl group by a triazole or
sulfonamide moiety leads to a complete loss of inhibition
against the three enzymes (Table 2, ESI Fig. S1†). Nevertheless,
introduction of a NHCOCF3 group (13a) provided a selective
and competitive NagZ inhibitor (Ki = 5.7 ± 0.5 μM, ESI Fig. S2†)
while longer NHCOCF2CF3 (13b) and NHCOCF2CF2CF3 (13c)
groups completely abolished NagZ inhibition. The substitution
of hydrogen for fluorine is a monovalent isosteric replacement
used widely in medicinal chemistry. This is due to the similar
steric parameters for the hydrogen and fluorine atoms
(van der Waals radii 1.2 and 1.35 Å). Fluorine, however, exerts
strong field and inductive effects on nearby atoms. Therefore,
the observed selectivity of 13a for NagZ may stem from subtle
steric or electronic effects.
Potentiation of the efficacy of ceftazidime
Since azepane 13a displayed fair potency and selectivity toward
NagZ, its ability to block NagZ in bacteria and attenuate
inducible AmpC-mediated β-lactam resistance within a rele-
vant bacterial model representative of clinically occurring
P. aeruginosa was evaluated. While 13a had no effect on its
Scheme 1 Synthesis of trihydroxylated azepanes bearing a triazole 9a–c,
a sulfonamide 11a–c or a fluorinated acetamide 13a–c moiety at C-3.
trials were disappointing and confirmed this practical issue. 
Using Williams’ one-pot strategy using non-volatile TMS-
alkynes28 proved unsuccessful with ethynyltrimethylsilane in 
our case. We were more successful with Kolarovič’s tandem 
catalysis protocol based on the decarboxylative coupling of 
alkynoic acids followed by 1,3-dipolar cycloaddition of 
azides.29 Using this procedure, azidoazepane 7 was efficiently 
clicked to butynoic, pentynoic and hexynoic acids in the pres-
ence of CuSO4 and sodium ascorbate under microwave acti-
vation at 80 °C to produce the 1,4-disubstituted triazoles 8a–c 
in 69–86% yield. Final hydrogenolysis using Pd black in a 
dichloroethane/water mixture under acidic conditions 
furnished the target triazolo-azepanes 9a–c.
Synthesis of sulfonamide derivatives. A Staudinger-mediated 
azide reduction of azepane 7 using supported triphenyl-
phosphine, followed by direct sulfonylation of the crude 
amine with the appropriate alkylsulfonyl chlorides afforded in 
satisfactory yields (57–75%) the corresponding sulfonamido-
azepanes 10a–c that were uneventfully and quantitatively 
deprotected by hydrogenolysis to yield the target sulfonamides 
11a–c.
Synthesis of fluoroalkyl derivatives. The length of the acet-
amido alkyl chain has been shown to be important for dis-
crimination between therapeutically relevant β-N-acetyl-
D-glucosaminidases OGA, HexA and NagZ. This difference 
stems from the shape of their specific binding pocket that 
accommodates the NHAc group. We reasoned that introduc-
tion of a fluorinated alkyl chain might be beneficial to selec-
tively target NagZ for electronic reasons according to the 
histidine environment of the NagZ active site. To this end, the 
crude amine resulting from azide reduction was acylated with 
perfluorinated alkyl chains of one, two or three carbons to 
furnish the corresponding amides 12a–c in good yield 
(56–91%). Their subsequent hydrogenolysis produced the 
target azepanes 13a–c (Scheme 1).
Biological evaluation of the polyhydroxylated azepanes
Inhibition of glycosidases. As a preliminary screen, poly-
hydroxylated azepanes 9a–c, 11a–c, 13a–c were evaluated as 
inhibitors of a collection of twenty glycosidases, including four 
hexosaminidases. Interestingly, none of these derivatives was 
shown to inhibit hexosaminidases at 1 mM concentration 
(Table 1). The triazole derivative 9c (R = Pr) weakly inhibited 
yeast α-glucosidase and E. coli β-glucuronidase, respectively. 
The sulfonamide analogs 11b (R = Et) and 11c (R = Pr) were 
identified as weak inhibitors of rice α-glucosidase and rat 
intestinal maltase as well as α- and β-galactosidases. In con-
trast, the fluoroalkyl derivatives 13b (R = Et) and 13c (R = Pr) 
showed weak but selective inhibition of rat intestinal cello-
biase. The propensity of these azepanes to mainly inhibit 
enzymes that process D-glucose-configured substrates is in 
accord with the gluco-like configuration of the azepane 
scaffold. The fact that derivatives 9c, 11b and 11c weakly 
inhibit glucosidases but not hexosaminidases suggests that 
the sulfonamide and triazole motifs are not recognized by 
these hexosaminidases as surrogates of the acetamido group.
Table 1 Concentration of polyhydroxylated azepanes giving 50% inhibition of various glycosidases
Enzyme
R= Me Et Pr Me Et Pr CF3 CF2CF3 CF2CF2CF3
9a 9b 9c 11a 11b 11c 13a 13b 13c
α-Glucosidase
Rice NIa (16.8%)b NI (19.5%) NI (29.7%) NI (33.3%) 307 383 NIa (8.6%)b NI (46.5%) NI (0.5%)
Yeast NI (9.4%) NI (41.1%) 130 NI (9.8%) NI (14.7%) NI (6.0%) NI (2.1%) NI (11.4%) NI (7.7%)
Rat intestinal maltase NI (10.6%) NI (14.6%) NI (11.8%) NI (15.0%) 814 NI (48.8%) NI (5.3%) NI (21.6%) NI (6.1%)
β-Glucosidase
Almond NI (5.2%) NI (10.3%) NI (25.0%) NI (2.9%) NI (5.51%) NI (5.9%) NI (49.6%) NI (0%) NI (36.4%)
Bovine liver NI (20.3%) NI (29.6%) NI (24.8%) NI (28.3%) NI (46.2%) NI (38.4%) 111 NI (17.6%) NI (47.7%)
Rat intestinal cellobiase NI (36.2%) NI (32.9%) NI (40.4%) NI (9.3%) NI (8.2%) NI (9.3%) 35 165 380
α-Galactosidase
Coffee beans NI (3.5%) NI (49.4%) NI (38.2%) NI (46.6%) 502 529 NI (1.2%) NI (0%) NI (3.5%)
β-Galactosidase
Bovine liver NI (14.2%) NI (34.0%) NI (39.2%) NI (41.6%) 503 627 47 NI (31.8%) NI (46.3%)
α-Mannosidase
Jack bean NI (0%) NI (0%) NI (2.9%) NI (0 %) NI (0%) NI (3.8%) NI (16.6%) NI (0.2%) NI (5.5%)
β-Mannosidase
Snail NI (1.6%) NI (0.61%) NI (1.1%) NI (1.8%) NI (0%) NI (0.92%) NI (0%) NI (0%) NI (2.0%)
α-L-Rhamnosidase
Penicillium decumbens NI (0%) NI (5.1%) NI (2.9%) NI (1.2%) NI (5.1%) NI (5.5%) NI (39.7%) NI (0%) NI (2.0%)
α-L-Fucosidase
Bovine kidney NI (6.8%) NI (4.4%) NI (9.9%) NI (3.6%) NI (6.3%) NI (11.8%) NI (22.0%) NI (0%) NI (11.2%)
β-Glucuronidase
E.coli NI (12.6%) NI (24.1%) 278 NI (15.7%) NI (20.4%) NI (38.4%) NI (18.2%) NI (14.6%) NI (13.5%)
Bovine liver NI (0%) NI (4.1%) NI (7.5%) NI (5.9%) NI (0%) NI (1.5%) NI (0%) NI (0%) NI (0%)
α,α-Trehalase
Porcine kidney NI (1.0%) NI (0%) NI (5.2%) NI (0%) NI (0%) NI (0%) NI (1.0%) NI (0%) NI (0%)
Amyloglucosidase
Rhizopus sp. NI (1.2%) NI (0%) NI (0%) NI (4.0%) NI (0%) NI (0.2%) NI (1.7%) NI (0%) NI (0%)
β-N-Acetylglucosaminidase
Bovine kidney NI (6.4%) NI (O%) NI (0%) NI (1.7%) NI (32.8%) NI (7.6%) NI (10.6%) NI (0%) NI (4.3%)
HL60 NI (30.3%) NI (7.1%) NI (8.4%) NI (5.2%) NI (32.0%) NI (0%) NI (34.3%) NI (0%) NI (13.8%)
Jack bean NI (0%) NI (7.8%) NI (3.2%) NI (0%) NI (0%) NI (O %) NI (5.6%) NI (0%) NI (6.3%)
α-N-Acetylgalactosaminidase
Chicken liver NI (0%) NI (3.7%) NI (0%) NI (0%) NI (40.8%) NI (5.3%) NI (0%) NI (0%) NI (0%)
aNI: No inhibition (less than 50% inhibition at 1000 μM). b ( ): Inhibition % at 1000 μM.
column chromatography was performed using silica gel 60
(Macherey–Nagel 60, 15–40 μm) or carried on a combiflash®
Rf automated apparatus (Teledyne-Isco) using columns speci-
fied in each protocol. NMR experiments were recorded with a
400 Bruker spectrometer at 400 MHz for 1H, 376 MHz for
19F and 100 MHz for 13C nuclei. The chemical shifts are
expressed in part per million (ppm) relative to TMS (δ =
0 ppm) and the coupling constant J in hertz (Hz). When
spectra were recorded in D2O, a drop of acetone or methanol
was added as an internal reference for calibration. NMR multi-
plicities are reported using the following abbreviations: b =
broad, s = singlet, d = doublet, t = triplet, q = quadruplet, m =
multiplet. HRMS were obtained with a Q-TOF spectrometer
from the Mass Spectrometry Service (IC2MP, UMR CNRS
7285-Poitiers University, France). Optical rotations were
measured using a Modular Circular Polarimeter MCP100
(Anton Paar).
General procedure A for click-chemistry reactions: To a
solution of azido azepane 7 in a dioxane/H2O (4 : 1,
24 mL mmol−1) mixture in a vial were added CuSO4, 5H2O
(0.6 eq.) and sodium ascorbate (5.0 eq.). The alkyne (20.0 eq.)
was then added and the vial was closed with a pierced rubber
septum. The reaction mixture was heated at 50 °C under MW
(50 W) during 1.5 h, by which time a TLC indicated total con-
version of the starting material. The mixture was diluted with
EtOAc, washed successively with NaHCO3 sat. and brine, dried
over Na2SO4 and concentrated in vacuo. The desired product
was obtained after purification over a flash chromatography
column.
General procedure B for the transformation of azido
azepane 7 into amido or sulfonamido azepanes: To a solution
of azido azepane 7 in THF (16.7 mL mmol−1) were added a
solution of NH4OH (28%) and triphenylphosphine polymer
bound (3 mmol g−1, 2.0 eq.). The resulting mixture was heated
at 45 °C for 24 h, by which time a TLC indicated total con-
sumption of the starting material. The mixture was filtered
over a pad of Celite®, eluted with MeOH and concentrated
in vacuo to give the amino azepane derivative as a colorless oil
in a quantitative yield.
To a solution of the crude amine in dry DCM
(9.4 mL mmol−1) under Ar was added Et3N (3.1 eq.) and the
reaction mixture was cooled at 0 °C. The electrophile (1.5 eq.)
was then added dropwise and the mixture was stirred for 1 h at
0 °C, by which time a TLC revealed no trace of the starting
material. The mixture was diluted with DCM, washed with HCl
1 M, neutralized with brine, dried over Na2SO4 and concen-
trated in vacuo. The desired product was obtained after purifi-
cation over a flash chromatography column.
General procedure C for deprotections by hydrogenolysis:
To a solution of the starting material in dichloroethane (52 mL
mmol−1) under Ar were added pure H2O (52 mL mmol
−1), HCl
12 M (1.0 eq.) and Pd black (starting material mass × 2). The
reaction mixture was stirred at 60 °C overnight under H2 atmo-
sphere, filtered over a pad of Celite® and eluted with MeOH.
After concentration in vacuo the desired product was obtained
without any further purification unless otherwise specified.
Compound O-GlcNAcase Ki (μM) NagZ Ki (μM) HexAB Ki (μM)
5 0.7 ± 0.1a 0.4 ± 0.2a 3.6 ± 0.9a
6 47 ± 3.0a 7.4 ± 0.5a NI
9a NI NI NI
11a NI NI NI
13a NI 5.7 ± 0.5 NI
13b NI NI NI
a Results determined previously.14 NI: IC50 experiments yielded no sig-
nificant inhibition at 0.46 mM concentration (see ESI Fig. S1).
Table 3 Susceptibility of PAΔdacB to β-lactam antibiotic ceftazidime in
the presence or absence of 1 mM azepane
Cefatzidime MICa (μg ml−1)
Strain
PAΔdacB − Azepane + Azepane 13a + Azepane 13c
32 24 32
aMICs were determined by the broth microdilution method using
cation adjusted Mueller–Hinton media according to CLSI guidelines.
Measurements were performed in duplicate.
Table 2 Inhibition of Salmonella typhimurium NagZ, human OGA, and 
human HexAB by azepane inhibitors
own on bacterial growth, use of 1 mM of 13a lowered the 
minimum inhibitory concentration (MIC) of P. aeruginosa 
ΔdacB by 25% from 32 μg ml−1 ceftazidime in the absence of 
inhibitor to 24 μg ml−1 (Table 3). In contrast, the more lipo-
philic derivative 13c had no effect on ceftazidime efficacy.
Conclusions
A series of analogs of AzeNAc 5, a submicromolar β-N-acetyl-
D-glucosaminidase inhibitor, modified at the acetamide 
moiety, have been synthesized in order to improve its selecti-
vity and potency toward NagZ, a key glycosidase involved in 
the inducible expression of AmpC β-lactamase that confers 
resistance to β-lactams antibiotics in many Gram negative 
bacteria. Interestingly, introduction of fluorinated acetamide 
moiety generated a selective albeit less potent NagZ inhibitor. 
This result suggests that introduction of a fluorinated acet-
amide group in GlcNAc-derived iminosugars represents a 
useful alternative to the NHAc bulk modification strategy to 
discriminate hexosaminidases that process GlcNAc conjugates. 
Work is in progress in our laboratory to further explore this 
finding.
Experimental
General methods
All commercial reagents were used as supplied. TLC plates 
were visualized under 254 nm UV light and/or by dipping the 
TLC plate into a solution of phosphomolybdic acid in ethanol 
(3 g per 100 mL) followed by heating with a heat gun. Flash
(18 H, m, CHAr), 7.11–6.99 (2 H, m, CHAr), 6.80 (0.5 H, s,
CHTria), 5.31 (0.5 H, d, J = 12.2 Hz, CH2Cbz), 5.20 (0.5 H, d, J =
12.2 Hz, CH2Cbz), 5.12 (0.5 H, d, J = 12.2 Hz, CH2Cbz), 4.99
(0.5 H, d, J = 12.2 Hz, CH2Cbz), 4.92 (0.5 H, t, J6,5 = 9.5 Hz,
H6), 4.84 (0.5 H, d, J = 12.3 Hz, CH2OBn), 4.77 (0.5 H, t, J =
8.9 Hz, H6), 4.63 (1 H, d, J = 11.6 Hz, CH2OBn), 4.58 (1 H, d,
J = 9.5 Hz, CH2OBn), 4.50 (0.5 H, dd, J5,6 = 9.4 Hz, J5,4 = 2.2 Hz,
H5), 4.47–4.40 (1.5 H, m, 0.5 H2, 0.5 H7′, 0.5 H5), 4.35 (0.5 H,
d, J = 11.2 Hz, CH2OBn), 4.31 (0.5 H, d, J = 11.3 Hz, CH2OBn),
4.27–4.10 (2 H, m, 0.5 H2′, 1.5 CH2OBn), 4.05–3.95 (1.5 H, m,
0.5 H7, 1 H4), 3.89 (0.5 H, t, J = 5.3 Hz, H3), 3.82–3.70 (1.5 H,
m, 0.5 H7′, 0.5 H7, 0.5 H3), 3.51 (0.5 H, d, J = 14.1 Hz, H2),
3.43 (0.5 H, d, J = 14.5 Hz, H2), 2.80 (1 H, q, J = 7.6 Hz, CH2Et),
2.69 (1 H, q, J = 7.6 Hz, CH2Et), 1.33 (1.5 H, t, J = 7.6 Hz,
CH3Et), 1.22 (1.5 H, t, J = 7.6 Hz, CH3Et);
13C NMR (100 MHz,
chloroform-d1): (presence of 2 rotamers) δ (ppm) = 156.6,
156.0 (CO), 148.9, 148.7 (CTria), 138.2, 137.9, 137.4, 137.4,
137.3, 137.3, 136.2 (Cipso), 128.8–126.9 (CHAr), 122.1, 121.6
(CHTria), 83.5, 83.4 (C5), 78.6, 78.5 (C4), 76.1 (C3), 73.3, 72.9,
72.4, 72.2, 71.4, 71.4 (CH2OBn), 67.6, 67.4 (CH2Cbz), 64.9, 64.2
(C6), 48.0, 47.4 (C7), 44.3, 43.5 (C2), 18.9, 18.8 (CH2Et), 13.6,
13.6 (CH3Et); HRMS (ESI+) m/z: [M + H]
+ calcd for C39H42N4O5:
647.3228, found: 647.3225.
Benzyl (3S,4R,5R,6S)-3,4,5-tris(benzyloxy)-6-(4-propyl-1H-1,2,3-
triazol-1-yl)azepane-1-carboxylate (8c). Compound 7 (63 mg,
0.11 mmol) was reacted with hexynoic acid (249.0 µL,
2.2 mmol) following general procedure A. The crude was puri-
fied over a flash chromatography column (Interchim® 50 µm
4 g, EtOAc/PE 0 : 1 to 6 : 4) to give 8c (54 mg, 74%) as a color-
less and transparent oil. Rf = 0.77 (EtOAc/PE 4 : 6); [α]20D =
+16.6° (c 9.1, CHCl3);
1H NMR (400 MHz, chloroform-d1):
(presence of 2 rotamers) δ (ppm) = 7.48 (0.5 H, s, CHTria),
7.40–7.19 (18 H, m, CHAr), 7.10–6.99 (2 H, m, CHAr), 6.79
(0.5 H, s, CHTria), 5.29 (0.5 H, d, J = 12.0 Hz, CH2Cbz), 5.18
(0.5 H, d, J = 12.2 Hz, CH2Cbz), 5.10 (0.5 H, d, J = 12.2 Hz,
CH2Cbz), 4.97 (0.5 H, d, J = 12.0 Hz, CH2Cbz), 4.91 (0.5 H, t,
J6,5 = 9.1 Hz, H6), 4.82 (0.5 H, d, J = 12.2 Hz, CH2OBn), 4.75
(0.5 H, t, J6,5 = 9.1 Hz, H6), 4.61 (1 H, d, J = 11.9 Hz, CH2OBn),
4.56 (1 H, d, J = 8.4 Hz, CH2OBn), 4.49 (0.5 H, dd, J5,6 = 9.2 Hz,
J5,4 = 1.9 Hz, H5), 4.46–4.39 (2 H, m, 0.5 H7′, 0.5 H2, 0.5 H5,
0.5 CH2OBn), 4.33 (0.5 H, d, J = 11.2 Hz, CH2OBn), 4.28 (0.5 H,
d, J = 11.3 Hz, CH2OBn), 4.24–4.10 (2.5 H, m, 2 CH2OBn, 0.5
H2′), 4.02–3.93 (1.5 H, m, 0.5 H7, 1 H4), 3.87 (0.5 H, t, J =
5.3 Hz, H3), 3.80–3.69 (1.5 H, m, 0.5 H7′, 0.5 H7, 0.5 H3), 3.49
(0.5 H, d, J = 14.2 Hz, 0.5 H2′), 3.42 (0.5 H, d, J = 14.5 Hz, 0.5
H2), 2.73 (1 H, t, J = 7.5 Hz, CH2CH2CH3), 2.61 (1 H, t, J =
7.3 Hz, CH2CH2CH3), 1.72 (1 H, sxt, J = 7.4 Hz, CH2CH2CH3),
1.61 (1 H, sxt, J = 7.3 Hz, CH2CH2CH3), 1.00 (1.5 H, t, J =
7.3 Hz, CH2CH2CH3), 0.95 (1.5 H, t, J = 7.3 Hz, CH2CH2CH3);
13C NMR (100 MHz, chloroform-d1): (presence of 2 rotamers)
δ (ppm) = 156.6, 156.1 (CO), 147.4, 147.2 (CTria), 138.2, 137.9,
137.5, 137.5, 137.4, 137.3, 136.2 (Cipso), 128.6–127.2 (CHAr),
122.4, 122.0 (CHTria), 83.5, 83.3 (C5), 78.7, 78.6 (C4), 76.1 (C3),
73.3, 72.9, 72.4, 72.2, 71.4, 71.4 (CH2OBn), 67.6, 67.5
(CH2Cbz), 65.0, 64.2 (C6), 48.0, 47.5 (C7), 44.3, 43.5 (C2), 27.6,
27.5 (CH2Pr), 22.6, 22.6 (CH2Pr), 13.8, 13.7 (CH3Pr); HRMS
Benzyl (3S,4R,5R,6S)-3-azido-4,5,6-tris(benzyloxy) azepane-1-
carboxylate (7).27 Rf = 0.53 (DCM/MeOH 95 : 5); [α]D20 = +5.8°
(c 1.0, CHCl3); 1H NMR (400 MHz, chloroform-d1): (presence 
of 2 rotamers) δ (ppm) = 7.37–7.11 (20 H, m, CHAr), 5.21–5.08 
(2 H, m, CH2Cbz), 4.80–4.77 (0.5 H, m, CH2OBn), 4.61–4.40 
(5.5 H, m, CH2OBn), 3.98 (0.5 H, dt, J3,2 = 7.7 Hz, J3,4 = 2.0 Hz, 
H3), 3.92 (0.5 H, dt, J3,2 = 7.7 Hz, J3,4 = 2.0 Hz, H3), 3.86–3.53 
(6.5 H, m, 1.5 H2, 1 H4, 1 H5, 1 H6, 1 H7), 3.46 (0.5 H, dd, 
J2,2′ = 14.7 Hz, J2,3 = 8 Hz, H2); 13C NMR (100 MHz, 
chloroform-d1): (presence of 2 rotamers) δ (ppm) = 156.3, 
156.2 (CO), 138.4, 138.2, 137.9, 137.7, 136.6, 136.4 (Cipso), 
128.7–127.5 (CHAr), 83.0, 82.4, 81.7, 81.1, 79.5, 78.6 (C4, 
C5, C6), 73.4, 73.2, 73.0, 71.8, 71.7 (CH2OBn), 67.9, 67.6 
(CH2Cbz), 64.1, 63.4 (C3), 46.1, 46.0 (C2), 44.9, 44.5 (C7); 
HRMS (ESI+) m/z: [M +  H]+ calcd for C35H37O5N4: 593.2764, 
found: 593.2763.
Benzyl (3S,4R,5R,6S)-3,4,5-tris(benzyloxy)-6-(4-methyl-1H-1,2,3-
triazol-1-yl)azepane-1-carboxylate (8a). Compound 7 (100 mg, 
0.17 mmol) was reacted with butynoic acid (286 mg, 
3.4 mmol) following general procedure A. The crude was puri-
fied over a flash chromatography column (Redisep® 4 g, 
EtOAc/PE 0 : 1 to 8 : 2) to give 8a (93 mg, 86%) as a colorless
and transparent oil. Rf = 0.71 (EtOAc/PE 4 : 6); [α]D20 = +28.7°
(c 0.3, CHCl3); 1H NMR (400 MHz, chloroform-d1): (presence 
of 2 rotamers) δ (ppm) = 7.34 (0.5 H, s, CHTria), 7.30–7.06 
(18 H, m, CHAr), 6.98–6.89 (2 H, m, CHAr), 6.58 (0.5 H, s, 
CHTria), 5.16 (0.5 H, d, J = 12.0 Hz, CH2Cbz), 5.06 (0.5 H, d, J = 
12.3 Hz, CH2Cbz), 4.98 (0.5 H, d, J = 12.2 Hz, CH2Cbz), 4.86 
(0.5 H, d, J = 12.0 Hz, CH2Cbz), 4.78 (0.5 H, td, J6,5 = 9.4 Hz, 
J6,7 = 1.5 Hz, H6), 4.70 (0.5 H, d, J = 12.2 Hz, CH2OBn), 4.62 
(0.5 H, td, J6,5 = 9.4 Hz, J6,7 = 1.0 Hz, H6), 4.49 (1 H, d, J = 
11.7 Hz, CH2OBn), 4.44 (1 H, d, J = 7.9 Hz, CH2OBn), 4.36 
(0.5 H, dd, J5,6 = 9.4 Hz, J5,4 = 2.1 Hz, H5), 4.33–4.26 (2 H, m, 
0.5 H2, 0.5 H7′, 0.5 H5, 0.5 CH2OBn), 4.22 (0.5 H, d, J = 
11.2 Hz, CH2OBn), 4.19–4.14 (0.5 H, m, CH2OBn), 4.12–3.95 
(2.5 H, m, 0.5 H2′, 2 CH2OBn), 3.89–3.79 (1.5 H, m, 1 H4, 0.5 
H7), 3.75 (0.5 H, s, H3), 3.67–3.56 (1.5 H, m, 0.5 H7′, 0.5 H7, 
0.5 H3), 3.37 (0.5 H, d, J = 14.2 Hz, 0.5 H2′), 3.29 (0.5 H, d, J = 
14.4 Hz, 0.5 H2), 2.25 (1.5 H, s, Me), 2.13 (1.5 H, s, Me); 
13C NMR (100 MHz, chloroform-d1): (presence of 2 rotamers) 
δ (ppm) = 156.6, 156.0 (CO), 142.4, 142.2 (CTria), 138.2, 137.9, 
137.5, 137.4, 137.3, 137.3, 136.2 (Cipso), 128.9–126.9 (CHAr), 
122.9, 122.5 (CHTria), 83.3, 83.1 (C5), 78.6, 78.5 (C4), 76.1 (C3), 
73.2, 72.8, 72.4, 72.2, 71.4, 71.3 (CH2OBn), 67.6, 67.4 
(CH2Cbz), 64.9, 64.2 (C6), 48.0, 47.5 (C7), 44.3, 43.4 (C2), 10.7, 
10.6 (Me); HRMS (ESI+) m/z: [M + H]+ calcd for C38H41N4O5: 
633.3071, found: 633.3088.
Benzyl (3S,4R,5R,6S)-3,4,5-tris(benzyloxy)-6-(4-ethyl-1H-1,2,3-
triazol-1-yl)azepane-1-carboxylate (8b). Compound 7 (112 mg, 
0.19 mmol) was reacted with pentynoic acid (373 mg, 
3.8 mmol) following general procedure A. The crude was puri-
fied over a flash chromatography column (Redisep® 4 g, 
EtOAc/PE 0 : 1 to 1 : 0) to give 8b (85 mg, 69%) as a colorless
and transparent oil. Rf = 0.15 (EtOAc/PE 2 : 8); [α]D20 = +2.1°
(c 0.2, CHCl3); 1H NMR (400 MHz, chloroform-d1): (presence 
of 2 rotamers) δ (ppm) = 7.49 (0.5 H, s, CHTria), 7.44–7.19
was reacted following general procedure B (acylation step
using MsCl (14.0 µL, 0.18 mmol)). A purification over a flash
chromatography column (Interchim® 50 µm 4 g, EtOAc/PE
0 : 1 to 3 : 7) afforded 10a (58 mg, 75%, 2 steps) as a colorless
and transparent oil. Rf = 0.65 (EtOAc/PE 4 : 6); [α]20D = −3.7°
(c 6.3, CHCl3);
1H NMR (400 MHz, chloroform-d1): (presence
of 2 rotamers) δ (ppm) = 7.51–7.26 (19 H, m, CHAr), 7.20 (1 H,
m, CHAr), 5.62 (0.5 H, d, JNH,6 = 6.7 Hz, NH), 5.53 (0.5 H, d,
JNH,6 = 6.6 Hz, NH), 5.23–5.08 (2 H, m, CH2Cbz), 4.81 (0.5 H, d,
J = 11.7 Hz, CH2OBn), 4.68–4.42 (5.5 H, m, CH2OBn), 4.21
(1 H, td, J7′,7 = 14.0 Hz, J = 3.4 Hz, H7′), 4.15–4.11 (0.5 H, m,
H6), 4.10 (0.5 H, m, H7), 4.06–4.02 (0.5 H, m, H4), 4.01–3.94
(2 H, m, 0.5 H3, 0.5 H4, 0.5 H5, 0.5 H2′), 3.90 (1 H, m, 0.5 H5,
0.5 H6), 3.79 (0.5 H, dt, J = 9.9 Hz, J = 3.9 Hz, H3), 3.54–3.47
(0.5 H, m, H2), 3.45–3.35 (1.5 H, m, 0.5 H7, 0.5 H2′, 0.5 H2),
3.04 (1.5 H, s, Me), 2.57 (1.5 H, s, Me); 13C NMR (100 MHz,
chloroform-d1): (presence of 2 rotamers) δ (ppm) = 156.2,
155.9 (CO), 138.0, 137.9, 137.1, 137.1, 137.0, 136.9, 136.2,
136.1 (Cipso), 129.3–126.5 (CHAr), 82.9, 82.6 (C4), 81.9, 80.8
(C3), 77.5, 77.1 (C5), 72.9, 72.9, 72.5, 72.4, 71.8, 71.7
(CH2OBn), 67.6, 67.6 (CH2Cbz), 54.9, 54.7 (C6), 48.0 (C2), 47.2
(C7), 46.9 (C7 or C2), 46.6 (C2 or C7), 42.4, 41.2 (Me); HRMS
(ESI+) m/z: [M + Na]+ calcd for C36H40N2NaO7S: 667.2448,
found: 667.2466.
Benzyl (3S,4R,5R,6S)-3,4,5-tris(benzyloxy)-6-(ethylsulfon-
amido)azepane-1-carboxylate (10b). Compound 7 (70 mg,
0.12 mmol) was reacted following general procedure B (acyl-
ation step using ClSO2Et (17.0 µL, 0.18 mmol)). A purification
over a flash chromatography column (Interchim® 15 µm 4 g,
EtOAc/PE 0 : 1 to 2 : 8) afforded 10b (45 mg, 57%, 2 steps) as a
colorless and transparent oil. Rf = 0.27 (EtOAc/PE 2 : 8); [α]20D =
−0.69° (c 5.8, CHCl3);1H NMR (400 MHz, chloroform-d1): (pres-
ence of 2 rotamers) δ (ppm) = 7.43–7.22 (19 H, m, CHAr),
7.19–7.13 (1 H, m, CHAr), 5.43 (0.5 H, d, JNH,6 = 6.6 Hz, NH),
5.37 (0.5 H, d, JNH,6 = 7.3 Hz, NH), 5.20–5.14 (0.5 H, m,
CH2Cbz), 5.12 (1 H, d, J = 2.2 Hz, CH2Cbz), 5.10–5.04 (0.5 H,
m, CH2Cbz), 4.77 (0.5 H, d, J = 11.6 Hz, CH2OBn), 4.66–4.36
(5.5 H, m, CH2OBn), 4.19 (0.5 H, t, J7,6 = 4.4 Hz, H7), 4.15
(0.5 H, t, J7,6 = 4.1 Hz, H7), 4.12–3.86 (4 H, m, 0.5 H3, 1 H4,
1 H5, 0.5 H6, 0.5 H7′, 0.5 H2′), 3.83 (0.5 H, d, J = 6.9 Hz, H6),
3.75 (0.5 H, dt, J = 9.9 Hz, J = 3.9 Hz, H3), 3.46 (0.5 H, dd, J2,2′ =
14.6 Hz, J2,3 = 2.1 Hz, H2), 3.41–3.31 (1.5 H, m, 0.5 H2′, 0.5 H2,
0.5 H7′), 3.15–3.02 (1 H, m, CH2Et), 2.66 (1 H, q, J = 7.4 Hz,
CH2Et), 1.31 (1.5H, t, J = 7.4 Hz, CH3Et), 1.05 (1.5 H, t, J =
7.4 Hz, CH3Et);
13C NMR (100 MHz, chloroform-d1): (presence
of 2 rotamers) δ (ppm) = 156.2, 156.0 (COCbz), 138.0, 137.9,
137.2, 137.2, 137.0, 136.3, 136.2 (Cipso), 129.3–126.6 (CHAr),
83.0 (C5), 82.6 (C4), 82.0 (C5), 81.0 (C3), 72.9, 72.9, 72.5, 72.3,
71.8, 71.7 (CH2OBn), 67.7, 67.6 (CH2Cbz), 54.9, 54.7 (C6), 48.7
(CH2Et), 48.2 (C2), 47.9 (CH2Et), 47.4 (C2 or C7), 46.9 (C2
or C7), 46.6 (C2 or C7), 8.1, 7.9 (CH3Et); HRMS (ESI+) m/z:
[M + Na]+ calcd for C37H42N2NaO7S: 681.2605, found: 681.2596.
Benzyl (3S,4R,5R,6S)-3,4,5-tris(benzyloxy)-6-(propylsulfon-
amido)azepane-1-carboxylate (10c). Compound 7 (60 mg,
0.11 mmol) was reacted following general procedure B (acyl-
ation step using PrSO2Cl (19.0 µL, 0.17 mmol)). A purification
(ESI+) m/z: [M + H]+ calcd for C40H44N4O5: 661.3385, found: 
661.3380.
(3S,4R,5R,6S)-3,4,5-Trihydroxy-6-(4-methyl-1H-1,2,3-triazol-1-yl) 
azepanium chloride (9a). Compound 8a (53 mg, 0.084 mmol) 
was deprotected following general procedure C. The crude was 
purified over a flash chromatography column (DCM/EtOH 96°
7 : 3) to give 9a (10 mg, 45%) as a colorless and transparent oil.
Rf = 0.21 (DCM/EtOH 96°7 : 3); [α]D20 = +0.9° (c 1.1, MeOH); 
1H NMR (400 MHz, D2O): δ (ppm) = 7.81 (1 H, s, CHTria), 5.18 
(1 H, td, J6,7 = 9.8 Hz, J6,7′ = 1.8 Hz, H6), 4.28 (1 H, t, J3,2′ = 
6.3 Hz, H3), 4.16 (1 H, dd, J5,6 = 9.7 Hz, J5,4 = 5.0 Hz, H5), 4.02 
(1 H, t, J4,5 = 5.4 Hz, H4), 3.81 (1 H, dd, J7,7′ = 13.9 Hz, J7,6 = 
10.0 Hz, H7), 3.67 (1 H, dd, J7′,7 = 13.8 Hz, J7′,6 = 2.0 Hz, H7′), 
3.55 (1 H, d, J2,2′ = 13.9 Hz, H2), 3.46 (1 H, dd, J2′,2 = 14.0 Hz, 
J2′,3 = 6.5 Hz, H2′), 2.31 (3 H, s, Me); 13C NMR (100 MHz, D2O): 
δ (ppm) = 144.1 (CTria), 123.8 (CHTria), 76.5 (C5), 75.4 (C4), 
67.3 (C3), 59.8 (C6), 46.2 (C7), 46.0 (C2), 9.6 (Me); HRMS (ESI+) 
m/z: [M  +  H]+ calcd for C9H17N4O3: 229.1295, found: 229.1303.
(3S,4R,5R,6S)-3-(4-Ethyl-1H-1,2,3-triazol-1-yl)-4,5,6-trihydroxy-
azepanium chloride (9b). Compound 8b (87 mg, 0.13 mmol) 
was deprotected following general procedure C to give 9b 
(32 mg) in a quantitative yield as a colorless and transparent
oil. Rf = 0.67 (DCM/MeOH 7 : 3); [α]D20 = −1.2° (c 1.0, MeOH); 
1H NMR (400 MHz, D2O): δ (ppm) = 8.35 (1 H, s, CHTria), 5.43 
(1 H, td, J3,4 = 9.8 Hz, J3,2′ = 2.4 Hz, H3), 4.32 (1 H, td, J6,5 = 
6.2 Hz, J6,7 = 1.5 Hz, H6), 4.20 (1 H, dd, J4,3 = 9.8 Hz, J4,5 = 
4.7 Hz, H4), 4.08 (1 H, dd, J5,6 = 6.2 Hz, J5,4 = 4.8 Hz, H5), 3.91 
(1 H, dd, J2,2′ = 14.1 Hz, J2,3 = 10.0 Hz, H2), 3.80 (1 H, dd, J2′,2 = 
13.9 Hz, J2′,3 = 2.0 Hz, H2′), 3.58 (1 H, dd, J7,7′ = 14.1 Hz, J7,6 = 
1.6 Hz, H7), 3.49 (1 H, dd, J7′,7 = 14.1 Hz, J7′,6 = 6.3 Hz, H7′), 
2.88 (2 H, q, J = 7.6 Hz, CH2Et), 1.31 (3 H, t, J = 7.6 Hz, CH3Et); 
13C NMR (100 MHz, D2O): δ (ppm) = 148.5 (CTria), 127.6 
(CHTria), 77.9 (C4), 76.6 (C5), 68.6 (C6), 63.5 (C3), 47.4 (C7), 
46.9 (C2), 18.4 (CH2Et), 13.3 (CH3Et); HRMS (ESI+) m/z:
[M + H]+ calcd for C10H18N4O3: 243.1452, found: 243.1458.
(3S,4R,5R,6S)-3,4,5-Trihydroxy-6-(4-propyl-1H-1,2,3-triazol-1-yl) 
azepanium chloride (9c). Compound 8c (53 mg, 0.08 mmol) 
was deprotected using general procedure C. The crude was 
purified over a flash chromatography column (DCM/EtOH 96°
7 : 3) to give 9c (14 mg, 60%) as a colorless and transparent oil.
Rf = 0.38 (DCM/EtOH 96°7 : 3); [α]D20 = −1.4° (c 1.5, MeOH); 
1H NMR (400 MHz, D2O): δ (ppm) = 7.95 (1 H, s, CHTria), 5.24 
(1 H, td, J6,7 = 9.8 Hz, J6,7′ = 2.3 Hz, H6), 4.30 (1 H, td, J3,2 = 
6.2 Hz, J3,2′ = 1.5 Hz, H3), 4.17 (1 H, dd, J5,6 = 9.8 Hz, J5,4 = 
5.0 Hz, H5), 4.04 (1 H, dd, J4,3 = 6.1 Hz, J4,5 = 5.1 Hz, H4), 3.84 
(1 H, dd, J7,7′ = 13.9 Hz, J7,6 = 10.0 Hz, H7), 3.70 (1 H, dd, J7′,7 = 
13.9 Hz, J7′,6 = 1.9  Hz, H7′), 3.57 (1 H, dd, J2′,2 = 13.9 Hz, J2′,3 = 1.5  
Hz, H2′), 3.48 (1 H, dd, J2,2′ = 14.0 Hz, J2,3 = 6.5  Hz, H2), 2.71 (2 H,  
t, J = 7.4 Hz, CH2CH2CH3), 1.67 (2 H, sxt, J = 7.4  Hz, CH2CH2CH3), 
0.90 (3 H, t, J = 7.4  Hz, CH2CH2CH3); 13C NMR (100  MHz,  D2O): 
δ (ppm) = 148.6 (CTria), 124.6 (CHTria), 77.1 (C5), 75.9 (C4), 67.8 
(C3), 60.8 (C6), 46.6 (C7), 46.5 (C2), 26.8 (CH2CH2CH3), 22.5 
(CH2CH2CH3), 13.3 (CH2CH2CH3); HRMS (ESI+) m/z: [M + H]+ 
calcd for C11H21N4O3: 257.1608, found: 257.1615.
Benzyl (3S,4R,5R,6S)-3,4,5-tris(benzyloxy)-6-(methylsulfonamido) 
azepane-1-carboxylate (10a). Compound 7 (70 mg, 0.12 mmol)
2
(CH3Et); HRMS (ESI+) m/z: [M + H]
+ calcd for C8H18N2O5S:
255.1009, found: 255.1007.
(3S,4R,5R,6S)-3,4,5-Trihydroxy-6-(propylsulfonamido)azepa-
nium chloride (11c). Compound 10c (47 mg, 0.07 mmol) was
deprotected following general procedure C to give 11c (21 mg)
in a quantitative yield as a colorless and transparent oil. Rf =
0.25 (DCM/MeOH 8 : 2); [α]20D = +27.6° (c 1.0, MeOH);
1H NMR
(400 MHz, D2O): δ (ppm) = 4.17 (1 H, td, J6,5 = 6.3 Hz, J =
1.9 Hz, H6), 3.92 (1 H, dd, J5,6 = 6.5 Hz, J5,4 = 5.1 Hz, H5), 3.87
(1 H, td, J3,4 = 9.8 Hz, J3,2′ = 2.2 Hz, H3), 3.66 (1 H, dd, J4,3 =
9.2 Hz, J4,5 = 5.0 Hz, H4), 3.49 (1 H, dd, J2′,2 = 13.7 Hz, J2′,3 =
2.1 Hz, H2′), 3.41–3.36 (1 H, m, H7′), 3.35–3.26 (2 H, m, H7,
H2), 3.26–3.20 (2 H, m, SO2CH2CH2CH3), 1.86–1.73 (2 H, m,
SO2CH2CH2CH3), 1.00 (3 H, t, J = 7.5 Hz, SO2CH2CH2CH3);
13C NMR (100 MHz, D2O): δ (ppm) = 76.5 (C4), 75.8 (C5), 68.0
(C6), 54.8 (CH2Pr), 54.3 (C3), 48.7 (C2), 46.3 (C7), 17.4 (CH2Pr),
12.6 (CH3Pr); HRMS (ESI+) m/z: [M + H]
+ calcd for
C9H20N2O5S: 269.1166, found: 269.1171.
Benzyl (3S,4R,5R,6S)-3,4,5-tris(benzyloxy)-6-(2,2,2-trifluoro-
acetamido)azepane-1-carboxylate (12a). Compound 7 (58 mg,
0.10 mmol) was reacted following general procedure B (acyla-
tion step using (CF3CO)2O (21.0 µL, 0.15 mmol)). A purifi-
cation over a flash chromatography column (Interchim®
15 µm 4 g, EtOAc/PE 0 : 1 to 1 : 9) afforded 12a (37 mg, 56%,
2 steps) as a colorless and transparent oil. Rf = 0.84 (EtOAc/PE
3 : 7); [α]20D = +21.0° (c 4.7, CHCl3);
1H NMR (400 MHz, chloro-
form-d1): (presence of 2 rotamers) δ (ppm) = 8.04 (0.5 H, d,
JNH,6 = 6.9 Hz, NH), 7.99 (0.5 H, d, JNH,6 = 7.0 Hz, NH),
7.43–7.28 (19 H, m, CHAr), 7.26–7.20 (1 H, m, CHAr),
7.14–7.07 (1 H, m, CHAr), 5.31 (0.5 H, d, J = 12.3 Hz, CH2Cbz),
5.23 (0.5 H, d, J = 12.2 Hz, CH2Cbz), 5.04 (0.5 H, d, J = 12.3 Hz,
CH2Cbz), 4.83 (0.5 H, d, J = 12.2 Hz, CH2Cbz), 4.80–4.74
(0.5 H, m, CH2OBn), 4.70–4.62 (1.5 H, m, CH2OBn), 4.60–4.51
(1.5 H, m, CH2OBn), 4.50–4.44 (0.5 H, m, CH2OBn), 4.42–4.32
(2.5 H, m, 0.5 H2′, 0.5 H2, 1 CH2OBn, 0.5 H6), 4.32–4.23 (2 H,
m, 0.5 H7, 1 CH2OBn, 0.5 H6), 4.17–4.08 (1.5 H, m, 0.5 H7′, 0.5
H4, 0.5 H3), 4.03–3.96 (1 H, m, 0.5 H4, 0.5 H5), 3.91 (0.5 H, t,
J = 4.8 Hz, H5), 3.86 (0.5 H, ddd, J = 10.2 Hz, J = 5.4 Hz, J =
2.4 Hz, H3), 3.44–3.29 (2 H, m, 0.5 H7′, 0.5 H7, 0.5 H2′, 0.5
H2); 13C NMR (100 MHz, chloroform-d1): (presence of 2 rota-
mers) δ (ppm) = 156.8, 156.7 (NHCO), 156.6 (COCbz), 156.5,
156.3 (NHCO), 155.9 (COCbz), 137.9, 137.8, 137.2, 137.0, 136.6,
136.4, 136.3, 136.1 (Cipso), 128.9–127.4 (CHAr), 116.9, 114.1
(CF3), 82.6, 81.8 (C4), 80.1 (C3), 75.6, 75.4 (C5), 72.8, 72.6, 72.5,
72.4, 71.9, 71.7 (CH2OBn), 67.5, 67.3 (CH2Cbz), 53.1, 52.6 (C6),
48.5, 48.1 (C7), 47.5, 46.4 (C2); 19F{1H} NMR (376 MHz, chloro-
form-d1): (presence of 2 rotamers) δ (ppm) = −76.26 (s),
−76.35 (s); HRMS (ESI+) m/z: [M + Na]+ calcd for
C37H37F3N2NaO6: 685.2496, found: 685.2500.
Benzyl (3S,4R,5R,6S)-3,4,5-tris(benzyloxy)-6-(2,2,3,3,3-penta-
fluoropropanamido) azepane-1-carboxylate (12b). Compound 7
(70 mg, 0.12 mmol) was reacted following general procedure B
(acylation step using (CF3CF2CO)2O (36.0 µL, 0.18 mmol)). A
purification over a flash chromatography column (Interchim®
15 µm 4 g, EtOAc/PE 0 : 1 to 1 : 9) afforded 12b (64 mg, 75%,
2 steps) as a colorless and transparent oil. Rf = 0.22 (EtOAc/PE
over a flash chromatography column (Interchim® 50 µm 4 g, 
EtOAc/PE 0 : 1 to 2 : 8) afforded 10c (42 mg, 57%, 2 steps) as a
colorless and transparent oil. Rf = 0.41 (EtOAc/PE 2 : 8); [α]D20 =
+4.6° (c 4.7, CHCl3); 1H NMR (400 MHz, chloroform-d1): (pres-
ence of 2 rotamers) δ (ppm) = 7.41–7.24 (19 H, m, CHAr), 
7.21–7.12 (1 H, m, CHAr), 5.44 (0.5 H, d, JNH,6 = 6.6 Hz, NH), 
5.37 (0.5 H, d, JNH,6 = 7.3 Hz, NH), 5.22–5.18 (0.5 H, m, 
CH2Cbz), 5.13 (1 H, d, J = 1.5 Hz, CH2Cbz), 5.10–5.05 (0.5 H, 
m, CH2Cbz), 4.79 (0.5 H, d, J = 11.7 Hz, CH2OBn), 4.68–4.37 
(5.5 H, m, CH2OBn), 4.23–4.14 (1 H, m, H7′), 4.14–4.08 (0.5 H, 
dd, J = 14.8 Hz, J = 3.1 Hz, H7), 4.06 (0.5 H, m, H6), 4.04–3.99 
(0.5 H, m, H4), 3.99–3.91 (1.5 H, m, 0.5 H3, 0.5 H4, 0.5 H5), 
3.90–3.84 (0.5 H, m, H5), 3.80 (0.5 H, t, J6,NH = 6.2 Hz, H6), 
3.76 (0.5 H, dt, J = 6.0 Hz, J = 3.9 Hz, H3), 3.48 (1 H, dd, J = 
14.5 Hz, J = 1.9 Hz, H2), 3.42–3.32 (1.5 H, m, 0.5 H7, 1 H2′), 
3.12–2.97 (1 H, m, CH2Pr), 2.67–2.59 (1 H, m, CH2CH2CH3), 
1.79 (1 H, sxt, J = 7.5 Hz, CH2CH2CH3), 1.57 (1 H, sxt, J = 
7.5 Hz, CH2CH2CH3), 1.02 (1.5 H, t, J = 7.4 Hz, CH2CH2CH3), 
0.82 (1.5 H, t, J = 7.4 Hz, CH2CH2CH3); 13C NMR (100 MHz, 
chloroform-d1): (presence of 2 rotamers) δ (ppm) = 156.2, 
156.0 (CO), 138.0, 137.9, 137.2, 137.1, 137.0, 136.3 (Cipso), 
128.5–127.5 (CHAr), 83.0, 82.6 (C4), 82.0, 81.0 (C3), 77.4, 77.2 
(C5), 72.9, 72.9, 72.4, 72.3, 71.8, 71.6 (CH2OBn), 67.6, 67.5 
(CH2Cbz), 56.0, 55.1 (CH2Pr), 54.9, 54.6 (C6), 48.3 (C2), 47.5 
(C7), 46.9 (C2), 46.6 (C7), 17.3, 17.0 (CH2Pr), 12.8, 12.7 
(CH3Pr); HRMS (ESI+) m/z: [M + H]+ calcd for C38H45N2O7S: 
673.2942, found: 673.2955.
(3S,4R,5R,6S)-3,4,5-Trihydroxy-6-(methylsulfonamido)azepa-
nium chloride (11a). Compound 10a (63 mg, 0.098 mmol) was 
deprotected following general procedure C to give 11a (27 mg) 
in a quantitative yield as a colorless and transparent oil. Rf = 
0.20 (DCM/MeOH 8 : 2); [α]D20 = +24.1° (c 1.0, MeOH); 
1H NMR 
(400 MHz, D2O): δ (ppm) = 4.16 (1 H, td, J = 6.3 Hz, J6,7 = 
2.0 Hz, H6), 3.92 (1 H, dd, J5,6 = 6.5 Hz, J5,4 = 5.1 Hz, H5), 3.90 
(1 H, td, J3,2′ = 9.8 Hz, J3,2 = 2.2 Hz, H3), 3.66 (1 H, dd, J4,3 = 
9.2 Hz, J4,5 = 5.1 Hz, H4), 3.50 (1 H, dd, J2,2′ = 13.9 Hz, J2,3 = 
2.2 Hz, H2), 3.39 (1 H, dd, J7,7′ = 13.9 Hz, J7,6 = 2.1 Hz, H7), 
3.32 (1 H, dd, J7′,7 = 13.9 Hz, J7′,6 = 6.3 Hz, H7′), 3.27 (1 H, dd, 
J2′,2 = 13.9 Hz, J2′,3 = 10.0 Hz, H2′), 3.14 (3 H, s, Me); 
13C NMR (100 MHz, D2O): δ (ppm) = 76.4 (C5), 75.9 (C4), 
68.0 (C3), 54.2 (C6), 48.5 (C7), 46.3 (C2), 40.9 (Me); HRMS 
(ESI+) m/z: [M + H]+ calcd for C7H16N2O5S: 241.0853, found: 
241.0857.
(3S,4R,5R,6S)-3-(Ethylsulfonamido)-4,5,6-trihydroxyazepanium 
chloride (11b). Compound 10b (47 mg, 0.083 mmol) was depro-
tected following general procedure C to give 11b (21 mg) in a 
quantitative yield as a colorless and transparent oil. Rf = 0.37 
(DCM/MeOH 7 : 3); [α]D20 = +37.3° (c 0.3, MeOH); 
1H NMR 
(400 MHz, D2O): δ (ppm) = 4.18 (1 H, td, J = 6.3 Hz, J3,2 = 
1.9 Hz, H3), 3.93 (1 H, dd, J4,3 = 6.5 Hz, J4,5 = 5.1 Hz, H4), 3.88 
(1 H, td, J6,5 = 9.8 Hz, J6,7 = 2.4 Hz, H6), 3.68 (1 H, dd, J5,6 = 
9.2 Hz, J5,4 = 5.1 Hz, H5), 3.51 (1 H, dd, J2,2′ = 13.8 Hz, J2,3 = 
1.9 Hz, H2), 3.40 (1 H, dd, J7,7′ = 14.1 Hz, J7,6 = 2.1 Hz, H7), 
3.36–3.20 (4 H, m, H7′, H2′, CH Et), 1.33 (3 H, t, J = 7.3 Hz, 
CH3Et); 13C NMR (100 MHz, D2O): δ (ppm) = 76.5 (C5), 75.8 
(C4), 67.9 (C3), 54.2 (C6), 48.7 (C7), 47.8 (CH2Et), 46.3 (C2), 7.8
−123.17 (s), −123.23 (dd, J = 374.7 Hz, J = 273.8 Hz); HRMS
(ESI+) m/z: [M + Na]+ calcd for C38H37F5N2O6: 735.2464, found:
735.2456.
Benzyl (3S,4R,5R,6S)-3,4,5-tris(benzyloxy)-6-(2,2,3,3,4,4,4-
heptafluorobutanamido) azepane-1-carboxylate (12c).
Compound 7 (60 mg, 0.11 mmol) was reacted following
general procedure B (acylation step using (CF3(CF2)2CO)2O
(41.0 µL, 0.17 mmol)). A purification over a flash chromato-
graphy column (Interchim® 50 µm 4 g, EtOAc/PE 0 : 1 to 1 : 9)
afforded 12c (76 mg, 91%, 2 steps) as a colorless and transpar-
ent oil. Rf = 0.31 (EtOAc/PE 1 : 9); [α]20D = +27.7° (c 5.9, CHCl3);
1H NMR (400 MHz, chloroform-d1): (presence of 2 rotamers)
δ (ppm) = 8.13 (0.5 H, d, JNH,6 = 6.9 Hz, NH), 8.09 (0.5 H, d,
JNH,6 = 7.0 Hz, NH), 7.42–7.28 (19 H, m, CHAr), 7.26–7.20 (1 H,
m, CHAr), 7.14–7.08 (1 H, m, CHAr), 5.36 (0.5 H, d, J = 12.5 Hz,
CH2Cbz), 5.23 (0.5 H, d, J = 12.2 Hz, CH2Cbz), 5.06 (0.5 H, d,
J = 12.2 Hz, CH2Cbz), 4.81 (0.5 H, d, J = 12.3 Hz, CH2Cbz), 4.78
(0.5 H, d, J = 11.6 Hz, CH2OBn), 4.71–4.62 (1.5 H, m, CH2OBn),
4.60–4.52 (1.5 H, m, CH2OBn), 4.47 (0.5 H, d, J = 11.9 Hz,
CH2OBn), 4.42–4.26 (3.5 H, m, 0.5 H2′, 0.5 H2, 1 CH2OBn,
1 H6, 0.5 H7), 4.17–4.06 (1 H, m, 0.5 H3, 0.5 H7′), 4.04–4.00
(0.5 H, m, H4), 3.97 (0.5 H, t, J = 5.0 Hz, H5), 3.91 (0.5 H, t, J =
4.9 Hz, H5), 3.87 (0.5 H, ddd, J = 10.2 Hz, J = 5.2 Hz, J = 2.9 Hz,
H3), 3.44–3.33 (2 H, m, 0.5 H7′, 0.5 H7, 0.5 H2′, 0.5 H2);
13C NMR (100 MHz, chloroform-d1): (presence of 2 rotamers)
δ (ppm) = 157.2, 157.0, 156.9, 156.6 (NHCO weak signal),
156.4, 155.9 (COCbz), 137.9, 137.8, 137.2, 137.0, 136.5, 136.4,
136.3, 136.2 (Cipso), 129.0–127.2 (CHAr), 82.4, 81.7 (C4),
80.2, 80.1 (C3), 75.9, 75.7 (C5), 72.8, 72.6, 72.5, 72.5, 71.8,
71.7 (CH2OBn), 67.5, 67.3 (CH2Cbz), 53.3, 52.9 (C6), 48.2,
47.8 (C7), 47.4, 46.4 (C2); 19F{1H} NMR (376 MHz, chloroform-
d1): (presence of 2 rotamers) δ (ppm) = −80.48 (q, J = 8.2 Hz),
−120.69 (s), −120.78 (ddq, J = 441.4 Hz, J = 277.9 Hz, J =
9.5 Hz), −126.83 (s), −126.97 (s); HRMS (ESI+) m/z: [M + H]+
calcd for C39H37F7N2O6: 763.2613, found: 763.2625.
(3S,4R,5R,6S)-3,4,5-Trihydroxy-6-(2,2,2-trifluoroacetamido)
azepanium chloride (13a). Compound 12a (40 mg,
0.06 mmol) was deprotected using general procedure C. The
crude was purified over a flash chromatography column (DCM/
EtOH 96°7 : 3) to give 13a (16 mg, 90%) as a colorless oil. Rf =
0.54 (DCM/EtOH 96°7 : 3); [α]20D = +18.9° (c 0.8, MeOH);
1H NMR (400 MHz, methanol-d4): δ (ppm) = 4.33 (1 H, dt,
J3,4 = 9.2 Hz, J3,2 = 6.1 Hz, H3), 3.99 (1 H, td, J6,7 = 6.2 Hz, J6,7′ =
1.9 Hz, H6), 3.86 (1 H, t, J = 5.5 Hz, H5), 3.76 (1 H, dd, J4,3 =
9.2 Hz, J4,5 = 4.9 Hz, H4), 3.28 (1 H, d, J7′,6 = 2.0 Hz, H7′), 3.17
(2 H, d, J2,3 = 6.0 Hz, H2), 3.11 (1 H, dd, J = 13.6 Hz, J7,6 =
6.0 Hz, H7); 13C NMR (100 MHz, methanol-d4): δ (ppm) =
158.8 (q, J = 36.8 Hz, CO), 117.4 (q, J = 286.8 Hz, CF3), 77.0
(C5), 76.7 (C4), 71.0 (C6), 53.7 (C3), 48.8 (C2, C7); 19F{1H} NMR
(376 MHz, methanol-d4): δ (ppm) = −75.85 (s); HRMS (ESI+)
m/z: [M + H]+ calcd for C8H14F3N2O4: 259.0900, found:
259.0902.
(3S,4R,5R,6S)-3,4,5-Trihydroxy-6-(2,2,3,3,3-pentafluoropropan-
amido)azepanium chloride (13b). Compound 12b (59 mg,
0.083 mmol) was deprotected using general procedure C to
give 13b (26 mg) in a quantitative yield as a colorless and
transparent oil. Rf = 0.46 (DCM/EtOH 96°7 : 3); [α]20D = +22.7°
(c 0.3, MeOH); 1H NMR (400 MHz, D2O): (presence of 2 rota-
mers) δ (ppm) = 4.49 (0.5 H, td, J = 10.0 Hz, J = 2.6 Hz, H6),
4.19–4.13 (1 H, m, H3), 3.93–3.85 (1.5 H, m, 0.5 H6, 1 H4),
3.83–3.76 (1 H, m, H5), 3.64 (1 H, dd, J2,2′ = 13.8 Hz, J2,3 =
2.2 Hz, H2), 3.45–3.28 (3 H, m, H2′, H7); 13C NMR (100 MHz,
D2O): (presence of 2 rotamers) δ (ppm) = 159.8 (t, J = 26.4 Hz,
CO), 76.7, 76.6 (C4), 75.6, 75.1 (C5), 67.8, 67.6 (C3), 50.1, 49.8
(C6), 46.5, 46.4 (C7), 44.9 (C2); 19F{1H} NMR (376 MHz, D2O):
(presence of 2 rotamers) δ (ppm) = −83.43 to −82.86 (3 F, m),
−123.16 to −122.72 (2 F, m); HRMS (ESI+) m/z: [M + H]+ calcd
for C9H14F5N2O4: 309.0868, found: 309.0865.
(3S,4R,5R,6S)-3-(2,2,3,3,4,4,4-Heptafluorobutanamido)-4,5,6-
trihydroxyazepanium chloride (13c). Compound 12c (37 mg,
0.049 mmol) was deprotected using general procedure C. The
crude was purified over a flash chromatography column (DCM/
EtOH 96°7 : 3) to give 13c (13 mg, 67%) as a colorless and
transparent oil. Rf = 0.56 (DCM/EtOH 96°7 : 3); [α]20D = +6.3°
(c 0.9, H2O);
1H NMR (400 MHz, D2O): δ (ppm) = 4.19–4.13
(1 H, m, H6), 3.94–3.84 (2 H, m, H5, H3), 3.80 (1 H, dd, J =
10.1 Hz, J = 5.3 Hz, H4), 3.65 (1 H, dd, J7,7′ = 13.9 Hz, J7,6 =
2.1 Hz, H7), 3.45–3.31 (3 H, m, H2, H7′); 13C NMR (100 MHz,
D2O): δ (ppm) = 159.6 (t, J = 26.4 Hz, CO), 76.7 (C5), 74.9 (C4),
69.1 (C6), 51.5 (C3), 47.5 (C7 or C2), 47.3 (C2 or C7); 19F{1H}
NMR (376 MHz, D2O): δ (ppm) = −80.69 to −80.87 (3 F, m),
−121.26 (2 F, m), −127.41 (2 F, br. s); HRMS (ESI+) m/z:
[M + H]+ calcd for C10H14F7N2O4: 359.0836, found: 359.0828.
Docking
Docking calculations for NagZ were performed with GOLD
using the structure 4MSS14 and a binding site defined as a
15 Å radius sphere centered on the NZ atom of Lys170.
GoldScore was used as a scoring function, and all other para-
meters had default values.
1 : 9); [α]D20 = +33.5° (c 0.2, CHCl3); 
1H NMR (400 MHz, chloro-
form-d1): (presence of 2 rotamers) δ (ppm) = 8.12 (0.5 H, d, 
JNH,6 = 6.7 Hz, NH), 8.09 (0.5 H, d, JNH,6 = 7.0 Hz, NH), 
7.42–7.26 (19 H, m, CHAr), 7.21 (1 H, s, CHAr), 7.14–7.09 (1 H, 
m, CHAr), 5.34 (0.5 H, d, J = 12.3 Hz, CH2Cbz), 5.21 (0.5 H, d, 
J = 12.2 Hz, CH2Cbz), 5.06 (0.5 H, d, J = 12.2 Hz, CH2Cbz), 
4.84–4.73 (1 H, m, 0.5 CH2OBn, 0.5 CH2Cbz), 4.68–4.60 (1.5 H, 
m, CH2OBn), 4.59–4.50 (1.5 H, m, CH2OBn), 4.48–4.43 (0.5 H, 
m, CH2OBn), 4.42–4.23 (3.5 H, m, 0.5 H7, 0.5 H2′, 0.5 H2, 
1 H6, 1 CH2OBn), 4.15–4.04 (1 H, m, 0.5 H7′, 0.5 H3), 
4.02–3.98 (1 H, m, H4), 3.96 (0.5 H, t, J = 5.0 Hz, H5), 3.89 (0.5 
H, t, J = 5.0 Hz, H5), 3.84 (0.5 H, ddd, J = 10.2 Hz, J = 5.1 Hz, 
J = 2.9 Hz, H3), 3.44–3.28 (2 H, m, 0.5 H2′, 0.5 H2, 0.5 H7′, 0.5 
H7); 13C NMR (100 MHz, chloroform-d1): (presence of 2 rota-
mers) δ (ppm) = 157.4, 157.2, 157.1, 156.9, 156.9 (NHCO), 
156.5, 156.0 (COCbz), 137.9, 137.8, 137.2, 137.0, 136.6, 136.4, 
136.3, 136.2 (Cipso), 128.8–127.4 (CHAr), 82.5, 81.8 (C4), 80.3 
(C3), 75.9, 75.6 (C5), 72.9, 72.6, 72.5, 72.5, 71.9, 71.7 
(CH2OBn), 67.5, 67.3 (CH2Cbz), 53.2, 52.7 (C6), 48.2, 47.8 (C7), 
47.3, 46.3 (C2); 19F{1H} NMR (376 MHz, chloroform-d1):
(presence of 2 rotamers) δ (ppm) = −82.77 (s), −82.93 (s),
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Biological assays
Glycosidase inhibition profiling was performed using appro-
priate p-nitrophenyl glycosides as substrates at the optimum 
pH of each enzyme. The reaction was stopped by adding 
400 mM Na2CO3. The released p-nitrophenol was measured 
spectrometrically at 400 nm.
Kinetic analysis of OGA, NagZ and HexAB inhibition
The Salmonella typhimurium NagZ and human OGA proteins 
were purified as previously described.30,31 Human placental 
HexAB was obtained as a mixture of HexA and HexB isozymes 
from Sigma (product number, A6152). Initial rate experiments 
were carried out in 384 well assay plates (Corning, #3702) at 
25 °C. The assay buffer for OGA and NagZ was PBS (pH 7.4), 
whereas the HexAB assay buffer consisted of (50 mM sodium 
citrate pH 5, 0.1% Triton X-100). A continuous assay was deve-
loped in which all reactions were initiated via the addition of 
pNP-GlcNAc substrate. The assay contained 100 nM NagZ, 30 
nM hOGA, or 200 nM HexAB in a final volume of 50 μL for Ki 
determination. The reaction progress was monitored continu-
ously at a wavelength of 405 nm using a SpectraMax i3x multi-
mode plate reader from Molecular Devices. Reaction velocities 
were assessed by linear regression of the progress curves over a 
10 min period. The amount of product liberated was assessed 
using a standard curve for pNP in PBS buffer. For IC50 experi-
ments (see Fig. S1†), 2KM of pNP-GlcNAc substrate was used 
(hOGA; 200 μM, NagZ; 120 μM, HexAB; 300 μM). For Ki experi-
ments, a total of 6–8 inhibitor concentrations were tested, 
ranging from 1/6 to 80 times the Ki value. The mode of in-
hibition was assessed using Lineweaver–Burk plots, and the 
data was globally fit to a competitive inhibition model to deter-
mine the Ki. Curve fitting was performed using GraphPad 
Prism, and error bars correspond to S.D. from quadruplicate 
reads. Data is displayed in Table 2, and representative Ki and 
LB-plots for 13a mediated NagZ inhibition are shown in ESI 
Fig. S2.†
Minimum inhibitory concentration assay (MIC)
MICs were performed in duplicate using the broth microdilu-
tion method (Clinical and Laboratory Standards Institute) in a 
96-well plate with appropriate serial dilutions of ceftazidime in 
100 μl of cation-adjusted Mueller–Hinton broth (MHB) con-
taining a final concentration of 1 mM 13a or 13c. To account 
for the DMSO used to dissolve 13a and 13b, an equivalent 
quantity of DMSO was added to MHB in control samples 
(DMSO control). Wells were inoculated with 100 μl of ∼105 
cells of P. aeruginosa ΔdacB grown to an optical density (OD600) 
of ∼0.5. MICs were determined after incubation of the cells for 
18 h at 37 °C in a shaker incubator.
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